Others have reported that knockdown of miR-543-3p rescued the function of glutamate transporter type 1 (GLT-1) in the Parkinson's disease (PD) model and alleviate dyskinesia, suggesting that knockdown of miR-543-3p may be used as a potential therapeutic target for PD [18]. This evidence concerns the gene SLC1A2 and Parkinson disease.